Defunct Company
Total Trials
10
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,666
NCT00093197
Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack
Phase: Phase 1/2
Role: Lead Sponsor
Start: Sep 30, 2004
Completion: Oct 31, 2006
NCT00785954
Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]
Phase: Phase 2
Start: Nov 30, 2008
Completion: May 31, 2011
NCT01015235
Safety and Efficacy Study of KAI-1678 to Treat Subjects With Postoperative Pain
Start: Dec 31, 2008
Completion: Feb 28, 2010
NCT01106716
Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia
Start: Mar 31, 2009
Completion: Apr 30, 2010
NCT01135108
Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Spinal Cord Injury
Completion: May 31, 2010
NCT01134549
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers
Phase: Phase 1
Start: Jun 9, 2010
Completion: Jul 31, 2010
NCT01134562
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
Start: Sep 7, 2010
Completion: Apr 2, 2011
NCT01254565
Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
Start: Feb 20, 2011
Completion: Aug 24, 2011
NCT01414114
Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder
Start: Dec 5, 2011
Completion: May 21, 2012
NCT01576146
Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism
Start: Mar 31, 2012
Completion: May 1, 2014